Clinical Trials
2 trialsNCT01295632 2015-08-27
Safety and Tolerability of Different Dose Combinations of Ridaforolimus With MK-2206 or MK-0752 for Participants With Advanced Cancer (MK-8669-049)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01220570 2015-01-21
The Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer (MK-8669-050)
Merck Sharp & Dohme LLC
Phase 1 Completed